Figure 6.

Enhancement of oridonin cytotoxicity with GSH synthesis inhibitor BSO. (A) EC109 cells were incubated with BSO (0.5 mM) or/and oridonin (10 μM) or APR-246 (10 μM) for 24 h. and cell viability was assessed using MTT. (B) Increased doses of oridonin enhance synergy with BSO. EC109 cells were incubated for 24 h with serial concentrations of oridonin in the presence of 0.5 mM BSO. (C) GSH analysis of EC109 cells treated with 10 μM oridonin or 10 μM APR-246 and/or 0.5 mM BSO. (D) ROS of EC109 cells were detected at 4 h post-treatment with oridonin (10 μM) or APR-246 (10 μM) and/or 0.5 mM BSO. **P < 0.01, compared to treatment with vehicle control or either of the compounds alone.